Mengis Capital Management Inc. and
Armstrong Henry H Associates Inc. both cut their position in
Waters Corporation ($WAT), while Shell Asset Management Co., KLP Kapitalforvaltning AS, and Jones Financial Companies Lllp have increased their stake. Major sales of the stock were also conducted by
Baldwin Wealth Partners and
Mountain Pacific Investment Advisers. Waters has decided to merge with BD's Biosciences & Diagnostic Solutions Business for high-volume regulated testing. Despite some stock weakness, experts believe strong fundamentals may underpin a rebound. Financial performance in Q2 and Q1 2025 highlighted strong sales growth leading to raised guidance. Further expansion of Waters' Biological Analysis Portfolio was made possible through the acquisition of Halo Labs. Waters' India operations have benefited from increasing demand for weight-loss drugs. A noteworthy $17.5 billion purchase has been made; Waters agreed to acquire a Becton unit amid tariff pressures. However, risks are involved in the merger that might weaken its competitive advantage.
TD Cowen downgraded stock price target to $322 due to merger focus. Despite facing forex challenges, Waters reported strong Pharma and PFAS growth in Q4 2024. Some lifestyle industry insiders warn Waters may have shown recent weaknesses, yet the financials appear robust.
Waters Corp WAT News Analytics from Wed, 12 Feb 2025 08:00:00 GMT to Sat, 11 Oct 2025 10:50:10 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -4
